The drug, which can be used in combination with insulin or other medications, helps in controlling blood sugar levels.
Boston CEO David Platt said this new option in treatments fits into their pipeline of other diabetes therapeutics, including Ipoxyn for limb ischemia and PAZ-320 for blood glucose management.
Boston chief technology officer Joan Sellers said this filing is an important milestone in their diabetes program.